Knees Boost Zimmer Biomet; Turnaround Continues, But FDA Woes Linger
Executive Summary
Zimmer Biomet reported Q4 results that reflected solid progress in the company’s turnaround efforts, with knees leading the charge. But the company is making slower-than-expected progress resolving FDA warning letter issues and faces a new bribery lawsuit in Mexico.
You may also be interested in...
Orthopedic Roundup: Zimmer Biomet, J&J, Smith & Nephew, Stryker Hope For Post-COVID Recovery As Elective Surgeries Restart
The big four companies in the orthopedics space hope that the restart of elective surgeries will make up for lost sales, but many uncertainties remain.
Medtech Giants Ready To Battle Frontrunner Intuitive Surgical In 'Soft Surgery Robotics'
The global market for robotic surgery systems is expected to reach $9.7bn by 2023. With medtech giants Medtronic, Johnson & Johnson and Zimmer Biomet launching robotic platforms in 2020, this market is set for a major shakeup.
Market Intel: Medtech Giants Ready To Battle Frontrunner Intuitive Surgical In 'Soft Surgery Robotics'
The global market for robotic surgery systems is expected to reach $9.7bn by 2023. With medtech giants Medtronic, Johnson & Johnson and Zimmer Biomet launching robotic platforms in 2020, this market is set for a major shakeup.